Literature DB >> 15081940

Validated liquid chromatographic determination of 5-fluorouracil in human plasma.

Ibrahim A Alsarra1, Mohammed N Alarifi.   

Abstract

A sensitive, reproducible, selective and accurate high performance liquid chromatographic (HPLC) method for the quantitative determination of 5-flurorouracil in plasma has been developed and validated using isocratic elution and UV detection. The method provides a selective quantifications of 5-flurorouracil without any interference of the endogenous uracil. The assay is performed after a double extraction of 5-flurorouracil and thymine (internal standard) from human plasma using ethyl acetate. The drug and the internal standard were eluted from a Genesis C(18) analytical column at ambient temperature with mobile phase consisting of methanol:water (10:90, v/v) adjusted to pH 3.2 with perchloric acid at a flow rate of 1.0 ml/min. The effluent was monitored with an ultraviolet detector at 260 nm. Quantification was achieved by the measurement of the peak-height ratios and the limit of quantification for 5-flurorouracil in plasma was 30 ng/ml. The retention times for 5-flurorouracil, uracil, and thymine were 4.5, 6.0, and 9.0, respectively. The intra-day coefficient of variation (CV) ranged from 1.35 to 4.53% at three different concentrations and the inter-day CVs varied from 1.29 to 4.98%. The relative and absolute recoveries varied from 96 to 101%. Stability tests showed that 5-flurorouracil is stable for at least 72 h in plasma after freezing. The simple method may permit the assessment of 5-flurorouracil plasma concentrations for pharmacokinetic studies in combination with clinical trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081940     DOI: 10.1016/j.jchromb.2004.01.043

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets.

Authors:  Nattawut Leelakanok; Sean M Geary; Aliasger K Salem
Journal:  J Pharm Sci       Date:  2017-10-12       Impact factor: 3.534

2.  An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

Authors:  Jennifer M Atkinson; Anang A Shelat; Angel Montero Carcaboso; Tanya A Kranenburg; Leggy A Arnold; Nidal Boulos; Karen Wright; Robert A Johnson; Helen Poppleton; Kumarasamypet M Mohankumar; Clementine Féau; Timothy Phoenix; Paul Gibson; Liqin Zhu; Yiai Tong; Chris Eden; David W Ellison; Waldemar Priebe; Dimpy Koul; W K Alfred Yung; Amar Gajjar; Clinton F Stewart; R Kiplin Guy; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

3.  Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Authors:  Karen D Wright; Vinay M Daryani; David C Turner; Arzu Onar-Thomas; Nidal Boulos; Brent A Orr; Richard J Gilbertson; Clinton F Stewart; Amar Gajjar
Journal:  Neuro Oncol       Date:  2015-11-04       Impact factor: 12.300

Review 4.  A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil.

Authors:  Khushaboo Pandey; Rama Shankar Dubey; Bhim Bali Prasad
Journal:  Indian J Clin Biochem       Date:  2015-02-15

5.  Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Authors:  V M Daryani; Y T Patel; M Tagen; D C Turner; A M Carcaboso; J M Atkinson; A Gajjar; R J Gilbertson; K D Wright; C F Stewart
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.